257 related articles for article (PubMed ID: 12019085)
1. Randomized controlled trial of sequential intravenous (i.v.) and oral moxifloxacin compared with sequential i.v. and oral co-amoxiclav with or without clarithromycin in patients with community-acquired pneumonia requiring initial parenteral treatment.
Finch R; Schürmann D; Collins O; Kubin R; McGivern J; Bobbaers H; Izquierdo JL; Nikolaides P; Ogundare F; Raz R; Zuck P; Hoeffken G
Antimicrob Agents Chemother; 2002 Jun; 46(6):1746-54. PubMed ID: 12019085
[TBL] [Abstract][Full Text] [Related]
2. An economic evaluation of sequential i.v./po moxifloxacin therapy compared to i.v./po co-amoxiclav with or without clarithromycin in the treatment of community-acquired pneumonia.
Drummond MF; Becker DL; Hux M; Chancellor JV; Duprat-Lomon I; Kubin R; Sagnier PP
Chest; 2003 Aug; 124(2):526-35. PubMed ID: 12907538
[TBL] [Abstract][Full Text] [Related]
3. The efficacy and safety of two oral moxifloxacin regimens compared to oral clarithromycin in the treatment of community-acquired pneumonia.
Hoeffken G; Meyer HP; Winter J; Verhoef L;
Respir Med; 2001 Jul; 95(7):553-64. PubMed ID: 11453311
[TBL] [Abstract][Full Text] [Related]
4. Moxifloxacin monotherapy compared to amoxicillin-clavulanate plus roxithromycin for nonsevere community-acquired pneumonia in adults with risk factors.
Portier H; Brambilla C; Garre M; Paganin F; Poubeau P; Zuck P
Eur J Clin Microbiol Infect Dis; 2005 Jun; 24(6):367-76. PubMed ID: 15944847
[TBL] [Abstract][Full Text] [Related]
5. Once-daily oral gatifloxacin vs three-times-daily co-amoxiclav in the treatment of patients with community-acquired pneumonia.
Lode H; Magyar P; Muir JF; Loos U; Kleutgens K;
Clin Microbiol Infect; 2004 Jun; 10(6):512-20. PubMed ID: 15191378
[TBL] [Abstract][Full Text] [Related]
6. Moxifloxacin monotherapy is effective in hospitalized patients with community-acquired pneumonia: the MOTIV study--a randomized clinical trial.
Torres A; Garau J; Arvis P; Carlet J; Choudhri S; Kureishi A; Le Berre MA; Lode H; Winter J; Read RC;
Clin Infect Dis; 2008 May; 46(10):1499-509. PubMed ID: 18419482
[TBL] [Abstract][Full Text] [Related]
7. A multinational, multicentre, non-blinded, randomized study of moxifloxacin oral tablets compared with co-amoxiclav oral tablets in the treatment of acute exacerbation of chronic bronchitis.
Schaberg T; Ballin I; Huchon G; Bassaris H; Hampel B; Reimnitz P;
J Int Med Res; 2001; 29(4):314-28. PubMed ID: 11675905
[TBL] [Abstract][Full Text] [Related]
8. A randomized trial of the efficacy and safety of sequential intravenous/oral moxifloxacin monotherapy versus intravenous piperacillin/tazobactam followed by oral amoxicillin/clavulanate for complicated skin and skin structure infections.
Gyssens IC; Dryden M; Kujath P; Nathwani D; Schaper N; Hampel B; Reimnitz P; Alder J; Arvis P
J Antimicrob Chemother; 2011 Nov; 66(11):2632-42. PubMed ID: 21896561
[TBL] [Abstract][Full Text] [Related]
9. Randomized controlled trial of moxifloxacin compared with piperacillin-tazobactam and amoxicillin-clavulanate for the treatment of complicated intra-abdominal infections.
Malangoni MA; Song J; Herrington J; Choudhri S; Pertel P
Ann Surg; 2006 Aug; 244(2):204-11. PubMed ID: 16858182
[TBL] [Abstract][Full Text] [Related]
10. SOLITAIRE-IV: A Randomized, Double-Blind, Multicenter Study Comparing the Efficacy and Safety of Intravenous-to-Oral Solithromycin to Intravenous-to-Oral Moxifloxacin for Treatment of Community-Acquired Bacterial Pneumonia.
File TM; Rewerska B; Vucinic-Mihailovic V; Gonong JRV; Das AF; Keedy K; Taylor D; Sheets A; Fernandes P; Oldach D; Jamieson BD
Clin Infect Dis; 2016 Oct; 63(8):1007-1016. PubMed ID: 27448679
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of ten day moxifloxacin 400 mg once daily in the treatment of patients with community-acquired pneumonia. Community Acquired Pneumonia Study Group.
Patel T; Pearl J; Williams J; Haverstock D; Church D
Respir Med; 2000 Feb; 94(2):97-105. PubMed ID: 10714413
[TBL] [Abstract][Full Text] [Related]
12. A randomized study of sequential intravenous/oral moxifloxacin in comparison to sequential intravenous ceftriaxone/oral cefuroxime axetil in patients with hospital-acquired pneumonia.
Höffken G; Barth J; Rubinstein E; Beckmann H;
Infection; 2007 Dec; 35(6):414-20. PubMed ID: 18034211
[TBL] [Abstract][Full Text] [Related]
13. Sequential IV/PO moxifloxacin treatment of patients with severe community-acquired pneumonia.
Lode H; Grossman C; Choudhri S; Haverstock D; McGivern J; Herman-Gnjidic Z; Church D
Respir Med; 2003 Oct; 97(10):1134-42. PubMed ID: 14561021
[TBL] [Abstract][Full Text] [Related]
14. The efficacy and safety of oral pharmacokinetically enhanced amoxycillin-clavulanate 2000/125 mg, twice daily, versus oral amoxycillin-clavulanate 1000/125 mg, three times daily, for the treatment of bacterial community-acquired pneumonia in adults.
Petitpretz P; Chidiac C; Soriano F; Garau J; Stevenson K; Rouffiac E;
Int J Antimicrob Agents; 2002 Aug; 20(2):119-29. PubMed ID: 12297361
[TBL] [Abstract][Full Text] [Related]
15. Five-day moxifloxacin therapy compared with 7-day co-amoxiclav therapy for the treatment of acute exacerbation of chronic bronchitis.
Starakis I; Gogos CA; Bassaris H
Int J Antimicrob Agents; 2004 Feb; 23(2):129-37. PubMed ID: 15013037
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of oral moxifloxacin in standard first-line therapy in community-acquired pneumonia.
Torres A; Muir JF; Corris P; Kubin R; Duprat-Lomon I; Sagnier PP; Höffken G
Eur Respir J; 2003 Jan; 21(1):135-43. PubMed ID: 12570122
[TBL] [Abstract][Full Text] [Related]
17. Microbiologic efficacy of moxifloxacin for the treatment of community-acquired pneumonia due to Chlamydia pneumoniae.
Hammerschlag MR; Roblin PM
Int J Antimicrob Agents; 2000 Jul; 15(2):149-52. PubMed ID: 10854812
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of intravenous moxifloxacin versus cefoperazone with azithromycin in the treatment of community acquired pneumonia.
Xu S; Xiong S; Xu Y; Liu J; Liu H; Zhao J; Xiong W
J Huazhong Univ Sci Technolog Med Sci; 2006; 26(4):421-4. PubMed ID: 17120738
[TBL] [Abstract][Full Text] [Related]
19. Moxifloxacin for the treatment of patients with complicated intra-abdominal infections (the AIDA Study).
Weiss G; Reimnitz P; Hampel B; Muehlhofer E; Lippert H;
J Chemother; 2009 Apr; 21(2):170-80. PubMed ID: 19423470
[TBL] [Abstract][Full Text] [Related]
20. Sequential intravenous/oral moxifloxacin versus intravenous piperacillin-tazobactam followed by oral amoxicillin-clavulanate for the treatment of complicated skin and skin structure infection.
Giordano P; Song J; Pertel P; Herrington J; Kowalsky S
Int J Antimicrob Agents; 2005 Nov; 26(5):357-65. PubMed ID: 16229991
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]